HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrea Vitali Selected Research

Proteasome Inhibitors

6/2012An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrea Vitali Research Topics

Disease

1Cognitive Dysfunction
05/2021
1Stroke (Strokes)
05/2021
1Lymphedema (Milroy Disease)
01/2021
1Spinal Cord Injuries (Spinal Cord Injury)
11/2020
1Infections
01/2013
1Neoplasms (Cancer)
06/2012
1Ovarian Neoplasms (Ovarian Cancer)
06/2012
1Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
03/2012

Drug/Important Bio-Agent (IBA)

1SolutionsIBA
11/2020
1Toll-Like Receptor 4IBA
01/2013
1LipopolysaccharidesIBA
01/2013
1Proteasome InhibitorsIBA
06/2012
1taxaneIBA
06/2012
1liposomal doxorubicin (Doxil)FDA Link
06/2012
1Bortezomib (Velcade)FDA Link
06/2012
1PlatinumIBA
06/2012
11-dodecylpyridoxal (PLD)IBA
06/2012

Therapy/Procedure

1Telerehabilitation
05/2021
1Compression Stockings
01/2021
1Cardiac Resynchronization Therapy
03/2012